SYPGN - Clinical: Syphilis Antibody, IgG, Serum

Test Catalog

Test Name

Test ID: SYPGN    
Syphilis Antibody, IgG, Serum

Useful For Suggests clinical disorders or settings where the test may be helpful

An aid in the diagnosis of active Treponema pallidum infection


Routine prenatal screening

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

If syphilis IgG is positive, no additional testing will be performed.

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Syphilis is a disease caused by infection with the spirochete Treponema pallidum. The infection is systemic and the disease is characterized by periods of latency. These features, together with the fact that Treponema pallidum cannot be isolated in culture, mean that serologic techniques play a major role in the diagnosis and follow-up of treatment for syphilis.


Historically, the serologic testing algorithm for syphilis included an initial nontreponemal screening test, such as the rapid plasma reagin (RPR) or the venereal disease research laboratory (VDRL) tests. Because these tests measure the host's antibody response to nontreponemal antigens, they lack specificity. Therefore, a positive result by RPR or VDRL requires confirmation by a treponemal-specific test, such as the fluorescent treponemal antibody-absorbed (FTA-ABS) or microhemagglutination assay (MHA-TP). Although the FTA-ABS and MHA-TP are technically simple to perform, they are labor intensive and require subjective interpretation by testing personnel.


Recently, EIA and multiplex flow immunoassays (MFI) were introduced to assess serologic response to Treponema pallidum. The Bio-Rad BioPlex Syphilis IgG assay is an example of MFI technology, which utilizes specific, treponemal antigens coated on microspheres for the detection of IgG-class antibodies to Treponema pallidum. The BioPlex Syphilis IgG assay is highly sensitive and specific (see Supportive Data), and allows for an objective interpretation of results. Due to several factors including the low prevalence of syphilis in the United States, the increased specificity of treponemal assays, and the objective interpretation of MFI and EIA technology, initial serologic testing by a treponemal-specific assay (eg, EIA or MFI) is now commonly performed in clinical laboratories. Specimens testing positive by the treponemal-specific assay are then tested by RPR to provide supplementary serologic data, as well as to provide an indication of the patient's disease state and history of treatment.


During early primary syphilis, the first antibodies to appear are of the IgM-class, with IgG-class antibodies reaching significant titers later in the primary phase. As the disease progresses into the secondary phase, IgG-class antibodies to Treponema pallidum reach peak titers, and may persist indefinitely regardless of the disease state or prior therapy.   


For prenatal syphilis screening, the IgG test is recommended. IgM testing should not be performed during routine pregnancy screening unless clinically indicated.


Treponema pallidum IgG antibodies persist indefinitely, regardless of the course of the disease. If treatment of an original Treponema pallidum infection was not monitored, a diagnosis of reinfection may actually represent either a resurgence of an inadequately treated earlier infection or persistent IgG antibodies from a resolved infection.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.


Interpretation Provides information to assist in interpretation of the test results

A positive IgG treponemal test suggests infection withTreponema pallidum at some point in the past, but does not distinguish between treated and untreated infections. This is because treponemal tests (eg, EIA, multiplex flow immunoassay, or fluorescent treponemal antibody-absorbed) may remain reactive for life, even following adequate therapy. Therefore, the results of a nontreponemal assay, such as rapid plasma reagin, are needed to provide information on a patient's disease state and history of therapy.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

This test is not offered as a screening or confirmatory test for blood donor specimens.


Despite active syphilis, serologic tests may be negative in severely immunosuppressed patients such as those with AIDS.


In very early cases of primary syphilis, both IgM and IgG serologies may be negative.


In cases of old, successfully treated infection (>10 years earlier), both IgG and IgM serologies may be negative.


Results should be considered in the context of all available clinical and laboratory data.

Supportive Data

To evaluate the accuracy of the BioPlex Syphilis IgG assay, 1,008 consecutive, unique serum specimens submitted for routine syphilis IgG testing by EIA were also tested on the BioPlex 2200. Specimens showing discrepant results were repeat tested by both methods, and also tested by Treponema pallidum-particle agglutination (TP-PA). The BioPlex 2200 Syphilis IgG assay correctly identified 77 (98.7%) of the 78 specimens that were positive by EIA. The EIA-positive, BioPlex-negative specimen was shown to be truly negative by TP-PA and repeat EIA. In addition, the BioPlex assay correctly identified 916 (98.5%) of the 930 specimens that were negative by EIA. Among the 14 BioPlex-positive, EIA-negative specimens, 8 were shown to be truly positive by TP-PA (see Table). The BioPlex Syphilis IgG assay demonstrated an adjusted sensitivity and specificity of 100% and 99.4%, respectively.


Table. Comparison of the Bio-Rad Syphilis IgG Assay and the Trep-Chek EIA Among Prospective Serum Specimens (n = 1,008). 



EIA Positive

EIA Negative


BioPlex Positive




BioPlex Negative








a. 8/14 positive by Treponema pallidum-particle agglutination (TP-PA) upon follow-up testing

b. Negative by EIA upon repeat testing


Sensitivity: 77/78 = 98.7% (95% Confidence intervals: 92.4%, 99.9%)

Specificity: 916/930 = 98.5% (95% Confidence intervals: 97.5%, 99.1%)

Clinical Reference Recommendations for in-depth reading of a clinical nature

Tramont EC: Treponema pallidum (Syphilis). In Principles and Practice of Infectious Diseases. Fifth edition. Edited by GL Mandell, JE Bennet, R Dolin. New York, Churchill Livingstone, 2000, pp 2474-2491